Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Alzheimer's Disease (AD) contributes to most cases of dementia. Its prominent
neuropathological features are the extracellular neuritic plaques and intercellular …

The risk-benefit profile of anti-Aβ monoclonal antibodies (mAbs) in Alzheimer's disease (AD)
remains unclear, especially concerning their safety and overall effects on AD progression …

Neurodegenerative diseases (NDs) such as Alzheimer disease (AD), Parkinson disease
(PD), and Huntington disease (HD) represent a major socio-economic challenge in view of …

Abstract In the Central Nervous System (CNS), neuroinflammation orchestrated by microglia
and astrocytes is an innate immune response to counteract stressful and dangerous insults …

In June 2021, the world was informed about a new drug for Alzheimer's disease approved
by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest …

Alzheimer's disease (AD) is the most common form of neurodegenerative disease and
disability in the elderly; it is estimated to account for 60%–70% of all cases of dementia …

Background Anti-amyloid vaccines may offer a convenient, affordable, and accessible
means of preventing and treating Alzheimer's disease. UB-311 is an anti–amyloid-β active …

Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most frequent
cause of progressive dementia in senior adults. It is characterized by memory loss and …